Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Boosting effect of high-dose influenza vaccination on innate immunity among elderly
Olivia Bonduelle, Tristan Delory, Isabelle Franco-Moscardini, Marion Ghidi, Selma Bennacer, Michele Wokam, Mathieu Lenormand, Melissa Petrier, Olivier Rogeaux, Simon de Bernard, Karine Alves, Julien Nourikyan, Bruno Lina, INFLUOMICS Study group, Behazine Combadiere, Cécile Janssen
Olivia Bonduelle, Tristan Delory, Isabelle Franco-Moscardini, Marion Ghidi, Selma Bennacer, Michele Wokam, Mathieu Lenormand, Melissa Petrier, Olivier Rogeaux, Simon de Bernard, Karine Alves, Julien Nourikyan, Bruno Lina, INFLUOMICS Study group, Behazine Combadiere, Cécile Janssen
View: Text | PDF
Clinical Research and Public Health Immunology Vaccines

Boosting effect of high-dose influenza vaccination on innate immunity among elderly

  • Text
  • PDF
Abstract

BACKGROUND The high-dose quadrivalent influenza vaccine (QIV-HD) showed superior efficacy against laboratory-confirmed illness compared with the standard-dose quadrivalent influenza vaccine (QIV-SD) in randomized controlled trials with the elderly. However, specific underlying mechanism remains unclear.METHODS This phase IV randomized controlled trial compared early innate responses induced by QIV-HD and QIV-SD in 59 individuals aged > 65 years. Systemic innate cells and gene signatures at day 0 (D0) and D1 as well as hemagglutinin inhibition antibody (HIA) titers at D0 and D21 after vaccination were assessed.RESULTS QIV-HD elicited robust humoral response with significantly higher antibody titers and seroconversion rates than QIV-SD. At D1 after vaccination, QIV-HD recipients showed significant reduction in innate cells, including conventional DCs and NK cells, compared with QIV-SD, correlating with significantly increased HIA titers at D21. Blood transcriptomic analysis revealed greater amplitude of gene expression in the QIV-HD arm, encompassing genes related to innate immune response, IFNs, and antigen processing and presentation, and correlated with humoral responses. Interestingly, comparative analysis with a literature dataset from young adults vaccinated with influenza standard-dose vaccine highlighted strong similarities in gene expression patterns and biological pathways with the elderly vaccinated with QIV-HD.CONCLUSION QIV-HD induces higher HIA titers than QIV-SD, a youthful boost of the innate gene expression significantly associated with high HIA titers.TRIAL REGISTRATION EudraCT no. 2021-004573-32.

Authors

Olivia Bonduelle, Tristan Delory, Isabelle Franco-Moscardini, Marion Ghidi, Selma Bennacer, Michele Wokam, Mathieu Lenormand, Melissa Petrier, Olivier Rogeaux, Simon de Bernard, Karine Alves, Julien Nourikyan, Bruno Lina, INFLUOMICS Study group, Behazine Combadiere, Cécile Janssen

×

Figure 4

Innate cellular responses following QIV-HD and QIV-SD vaccination in elderly.

Options: View larger image (or click on image) Download as PowerPoint
Innate cellular responses following QIV-HD and QIV-SD vaccination in eld...
(A) Radar chart presents the 1 and –1 FC (log2) for participant groups. The medians of each blood cell population (T and B cells; neutrophils; basophils; CD56bright early and CD56dim NK cells; classical, intermediate, and nonclassical monocytes; pDCs, cDC1, cDC2, and moDCs) are presented for QIV-SD (green) and QIV-HD (violet) groups. (B) Violin plot of log2 FC (D1/D0) are represented for CD56bright early NK cells and cDC2 for 2 vaccinated groups. (C) Principal component analysis (PCA) representation of QIV-SD (green) and QIV-HD (violet) groups based on induced blood cell populations at D1/D0. Arrows indicate the prominent parameter distinguishing features (neutrophils, CD56bright early NK cells and cDC2). (D) Venn diagram of common DEG correlated with anti–A H3N2 (green) and –A H1N1 (yellow) HIA titers, CD56bright early NK cell FC (blue), and cDC2 FC (red). (E) STRING pathway analysis (with 3 K-means clustering represented by 3 node colors) of 46 genes are in common between all these 4 parameters. Statistical analyses were performed with 1-way ANOVA and Bonferroni’s multiple-comparison tests, and indicated as adjusted P values. **P < 0.01, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts